Öznur Öner

Dr. Öznur Öner


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in Medicina
Verified
Journal Article
Open access
PDF file
CACanan Akkus
Canan Akkus
ÖÖÖznur Öner
Öznur Öner
AKAtilla Okan Kilic
Atilla Okan Kilic
CDCevdet Duran
Cevdet Duran
Background and Objectives: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder often associated with metabolic disturbances such as insulin resistance and metabolic syndrome (MetS). Visceral adiposity index (VAI) is a validated marker that reflects visceral fat distribution and cardiometabolic risk. This study aimed to compare VAI levels among different PCOS phenotypes to evaluate cardiometabolic risk across these phenotypes. Materials and Methods: This prospective case–control study included 180 PCOS patients and 51 healthy controls without any metabolic or reproductive issues. Patients were divided into the following subtypes based on the Rotterdam criteria: Phenotype A (n = 96), clinical and/or biochemical hyperandrogenism (HA) + oligo-anovulation (OA) + polycystic ovarian morphology (PCOM); Phenotype B (n = 19), HA + OA; Phenotype C (n = 35), HA + PCOM; and Phenotype D (n = 30), OA + PCOM. VAI was calculated for women using anthropometric and biochemical parameters. Results: In the total PCOS group, VAI levels were significantly higher than in controls (p < 0.001). Phenotypes A and B had higher VAI values than controls and also higher in Phenotype A than in Phenotypes C and D (p = 0.003 and p = 0.001, respectively). While present in 38 patients (21.10%) in the PCOS group, there was no metabolic syndrome (MetS) in controls (p < 0.001). In Phenotypes A, B, and D, while more patients had MetS than controls (p < 0.001, 0.004, and 0.021, respectively), more patients had MetS in Phenotype A compared to Phenotypes C and D (p = 0.003 and p = 0.021, respectively). Given ROC analysis, the VAI cut-off value in predicting MetS in the PCOS group was 1.66 (sensitivity = 94.74% and specificity = 83.10%). Conclusions: PCOS phenotypes characterized by HA and OA, particularly Phenotypes A and B, are associated with higher VAI values and an increased frequency of MetS risk. Early identification of these phenotypes may facilitate the implementation of targeted metabolic risk reduction and early intervention strategies, thereby contributing to the reduction of cardiovascular risk.

18 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
CACanan Akkus
Canan Akkus
ÖÖÖznur Öner
Öznur Öner
AKAtilla Okan Kilic
Atilla Okan Kilic
CDCevdet Duran
Cevdet Duran
Background and Objectives: We aimed to compare visceral adiposity index (VAI) levels among polycystic ovary syndrome (PCOS) subtypes in this study. Matherials and Methods: A total of 180 PCOS patients and 51 controls were included. Patients were divided into the following subtypes: Phenotype A (n=96), clinical and/or biochemical hyperandrogenism (HA)+oligo-anovulation (OA)+polycystic ovarian morphology (PCOM); Phenotype B (n=19), HA+OA; Phenotype C (n=35), HA+PCOM; and, Phenotype D (n=30), OA+PCOM. VAI was calculated for women by the following formula: (Waist circumference/[36.58+(1.89xBody mass index)])x[(triglyceride(mmol/L)/0.81)x(1.52xHigh density lipoprotein-cholesterol(mmol/L))]. Results: In the total PCOS patients, VAI levels were higher than controls [1.21 (0.39-10.89) and 0.85 (0.32-1.87), respectively] (p< 0.001). VAI levels were higher in Phenotype A [1.46 (0.39-10.89)] and Phenotype B [1.31 (0.43-4.39)] than in controls [0.85 (0.32-1.87)], and also higher in Phenotype A than in Phenotype C [1.00 (0.41-4.79)] and Phenotype D [1.01 (0.4-3.21)] (p=0.003 and p=0.001, respectively). While present in 38 patients (21.1%) in the PCOS group, there was no metabolic syndrome (MetS) in controls (p< 0.001). In Phenotypes A, B, and D, while more patients had MetS than controls (p< 0.001, 0.004, and 0.021, respectively), more patients had MetS in Phenotype A, compared to Phenotypes C and D (p=0.003 and p=0.021, respectively). Given ROC analysis, the VAI cut-off value in predicting MetS in the PCOS group was 1.66 (sensitivity: 94.74% and specificity: 83.1%). Conclusions: PCOS phenotypes characterized by HA and OA, particularly Phenotypes A and B, are associated with higher VAI values and an increased frequency of MetS, underscoring the importance of early metabolic assessment in these patient groups.

13 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ÖÖÖznur Öner
Öznur Öner
CACanan Akkus
Canan Akkus
DDDoga Demircioglu
Doga Demircioglu
IKilhan karanlık
ilhan karanlık
CDCevdet Duran
Cevdet Duran
Background/Aim: Albuminuria is an established marker of endothelial dysfunction and an independent predictor of cardiovascular risk. Polycystic ovary syndrome (PCOS) is associated with early metabolic and vascular abnormalities; however, whether urinary albumin excretion differs across PCOS phenotypes remains unclear. This study aimed to evaluate urinary albumin excretion using the urinary albumin-to-creatinine ratio (U-ACR) across distinct PCOS phenotypes and to examine its association with metabolic parameters. Materials and Methods: In this cross-sectional study, 180 women aged 18-35 years with PCOS and 51 age-matched healthy controls were included. PCOS phenotypes were classified according to the Rotterdam criteria as Phenotype A (n = 96), Phenotype B (n = 19), Phenotype C (n = 35), and Phenotype D (n = 30). Insulin resistance was assessed using the homeostasis model assessment for insulin resistance (HOMA-IR). Urinary albumin and creatinine levels were measured in morning urine samples, and U-ACR was calculated. Results: Age was comparable across all groups. Body mass index, waist circumference, diastolic blood pressure, and HOMA-IR were significantly higher in Phenotype A compared with controls and other phenotypes, indicating a more adverse metabolic profile. Serum creatinine levels were similar across all groups. Despite this unfavorable metabolic profile in Phenotype A, U-ACR was significantly elevated only in Phenotype B compared with controls (p = 0.018) and Phenotype D (p = 0.016). No significant correlations were observed between U-ACR and age, body mass index, or HOMA-IR. When participants were categorized according to U-ACR levels (< 30, 30-299.9, and ≥ 300 mg/g creatinine), no significant differences in category distribution were observed between the total PCOS cohort, phenotype subgroups, and controls. Conclusion: Among PCOS phenotypes, U-ACR elevation was observed exclusively in Phenotype B despite similar renal function markers. Notably, this occurred even though Phenotype A exhibited a more adverse metabolic profile, suggesting a dissociation between metabolic burden and early microvascular involvement across PCOS phenotypes. These findings indicate that vascular risk in PCOS may be phenotype-dependent and support the potential value of phenotype-oriented cardiovascular risk assessment.

25 June 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
ÖÖÖznur Öner
Öznur Öner
CACanan Akkus
Canan Akkus
DDDoga Demircioglu
Doga Demircioglu
IKilhan karanlık
ilhan karanlık
CDCevdet Duran
Cevdet Duran
Background/Aim: Albuminuria is a clinical marker associated with microvascular involvement and an independent predictor of cardiovascular risk. Polycystic ovary syndrome (PCOS) is associated with early metabolic and vascular abnormalities; however, whether albumin excretion differs across PCOS phenotypes remains unclear. This study aimed to evaluate the urinary albumin-to-creatinine ratio (U-ACR) across PCOS phenotypes and to examine its association with metabolic parameters. Materials and Methods: In this cross-sectional study, 180 women aged 18–35 years with PCOS and 51 age-matched healthy controls were included. PCOS phenotypes were classified according to the Rotterdam criteria as Phenotype A (n = 96), Phenotype B (n = 19), Phenotype C (n = 35), and Phenotype D (n = 30). Insulin resistance was assessed using the homeostasis model assessment for insulin resistance (HOMA-IR). Urinary albumin and creatinine levels were measured in morning urine samples, and U-ACR was calculated. Results: Age was comparable across all groups. Body mass index, waist circumference, diastolic blood pressure, and HOMA-IR were significantly higher in Phenotype A compared with controls and other phenotypes, reflecting a more adverse metabolic profile. Serum creatinine levels were similar across all groups. Despite this metabolic profile in Phenotype A, U-ACR was significantly elevated only in Phenotype B compared with controls (p = 0.018), and Phenotype D (p = 0.016). No significant correlations were observed between U-ACR and age, body mass index, or HOMA-IR. When participants were categorized according to U-ACR levels (<30, 30–299.9, and ≥300 mg/g creatinine), no significant differences in category distribution were observed between the total PCOS cohort, phenotype subgroups, and controls. Conclusion: Among PCOS phenotypes, U-ACR elevation was observed exclusively in Phenotype B despite similar renal function markers. This finding, in the presence of a more adverse metabolic profile in Phenotype A, suggests a dissociation between metabolic burden and early microvascular involvement across PCOS phenotypes. These findings suggest a potential phenotype-specific pattern that warrants further investigation.

29 December 2019 in Aegean Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
ÖÖÖznur Öner
Öznur Öner
AÖAykut Özcan
Aykut Özcan
ZÇZeynep Çankaya
Zeynep Çankaya
The extrauterine migration of an intrauterine device (IUD) can be life-threatening and may require emergent surgical intervention and treatment. A case report where an ectopic IUD located on sigmoid colon within peritoneal cavity in a 40-year-old multigravida was successfully removed by laparoscopy is described. Although the practicality and success of this method depends on the position and location of the ectopic IUD and on the extent to which the device is imbedded, this case suggests that removal of the migrated IUD from the peritoneal cavity is an additional possibility for use of the laparoscope.